New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

 

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Follow us on social media for the latest updates in B2B!

Image

Latest

creative career
Crafted Journey How To: Building a Creative Career Across Scripts, Stages, and Sound
June 8, 2026

Creative careers rarely move in a straight line, especially for writers working across stage, screen, audio, books, and independent film. Sustaining that kind of life often means finding opportunities wherever they appear, building a strong network, staying open to different formats, and saying yes to collaborations that can lead somewhere unexpected. The stakes are…

Read More
EMR
EMR Strategy, Consulting, and Career Pivots with MedSys Co-Founder Mark Embry
June 8, 2026

Electronic medical records (EMRs) have moved from a back-office upgrade to a frontline determinant of care quality, clinician burnout, and hospital economics. With U.S. hospitals often spending tens to hundreds of millions—sometimes exceeding $100 million—on EMR implementations, the stakes have never been higher for getting both the technology and the human adoption right. As…

Read More
radiology
Growing Without Compromise: How Vision Radiology Balances Scale, AI, and Clinical Quality
June 4, 2026

Radiology sits at the center of a modern healthcare squeeze: imaging volumes are climbing, hospitals need faster reads, and there simply are not enough radiologists to meet demand the old way. At the same time, remote work and AI are reshaping what a clinical practice can look like. The challenge is no longer whether…

Read More
Radar
Physical Retail’s Next Infrastructure Layer: Item-Level Intelligence with Radar
June 4, 2026

Physical retail is under pressure to become as measurable and responsive as e-commerce. While retailers have spent years optimizing digital channels with real-time data, store teams have often had to make decisions with incomplete inventory visibility and delayed operational signals. That gap matters because stores still account for 80% of U.S. retail sales, making…

Read More